BR112022010611A2 - Compostos heterocíclicos como moduladores de estimulador de genes de interferon (sting) - Google Patents

Compostos heterocíclicos como moduladores de estimulador de genes de interferon (sting)

Info

Publication number
BR112022010611A2
BR112022010611A2 BR112022010611A BR112022010611A BR112022010611A2 BR 112022010611 A2 BR112022010611 A2 BR 112022010611A2 BR 112022010611 A BR112022010611 A BR 112022010611A BR 112022010611 A BR112022010611 A BR 112022010611A BR 112022010611 A2 BR112022010611 A2 BR 112022010611A2
Authority
BR
Brazil
Prior art keywords
sting
modulators
interferon gene
heterocyclic compounds
compounds
Prior art date
Application number
BR112022010611A
Other languages
English (en)
Inventor
Izabela Zawadzka Magdalena
Piero Stasi Luigi
Wojciech Cwiertnia Grzegorz
Piotr Dudek Lukasz
Justyna Gibas Agnieszka
Rajda Anna
Fabritius Charles-Henry
Radzimierski Adam
Ravindra Mahajan Tushar
Wojciech Les Marcin
Zuchowicz Karol
Wronowski Marek
Jörg Synak David
Raghuram Tangirala Sundara
Krzysztof Rogacki Maciej
Original Assignee
Ryvu Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics S A filed Critical Ryvu Therapeutics S A
Publication of BR112022010611A2 publication Critical patent/BR112022010611A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSTOS HETEROCÍCLICOS COMO MODULADORES DE ESTIMULADOR DE GENES DE INTERFERON (STING). A presente invenção refere-se a compostos de fórmula (I) e sais, estereoisômeros, tautômeros ou N-óxidos dos mesmos que são úteis como moduladores de STING (Estimulador de Genes de Interferon). A presente invenção se refere ainda aos compostos de fórmula (I) para uso como medicamento e a uma composição farmacêutica que compreende os ditos compostos.
BR112022010611A 2019-12-11 2020-12-11 Compostos heterocíclicos como moduladores de estimulador de genes de interferon (sting) BR112022010611A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19460064 2019-12-11
PCT/EP2020/085840 WO2021116451A1 (en) 2019-12-11 2020-12-11 Heterocyclic compounds as modulators of stimulator of interferon genes (sting)

Publications (1)

Publication Number Publication Date
BR112022010611A2 true BR112022010611A2 (pt) 2022-09-06

Family

ID=69137701

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010611A BR112022010611A2 (pt) 2019-12-11 2020-12-11 Compostos heterocíclicos como moduladores de estimulador de genes de interferon (sting)

Country Status (11)

Country Link
US (1) US20230076506A1 (pt)
EP (1) EP4073063A1 (pt)
JP (1) JP7426486B2 (pt)
KR (1) KR20220113473A (pt)
CN (1) CN114787147A (pt)
AU (2) AU2020400010B2 (pt)
BR (1) BR112022010611A2 (pt)
CA (1) CA3159968A1 (pt)
IL (1) IL293527A (pt)
MX (1) MX2022007178A (pt)
WO (1) WO2021116451A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113950473A (zh) * 2019-06-12 2022-01-18 雷沃医疗有限公司 干扰素基因刺激物(sting)的下一代调节剂
IL288868B1 (en) * 2019-06-12 2024-10-01 Ryvu Therapeutics S A Next generation modulators of stimulator of interferon genes (STING)
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
AU2007247385B2 (en) * 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
EP2365749A4 (en) * 2008-11-13 2012-05-30 Merck Sharp & Dohme QUINOLONE ANTAGONISTS OF THE NEUROPEPTIDE S RECEPTOR
GB2563642A (en) * 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
WO2019023635A1 (en) * 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
WO2019182886A1 (en) * 2018-03-20 2019-09-26 Merck Sharp & Dohme Corp. Oxo-tetrahydro-isoquinoline carboxylic acids as sting inhibitors
EP3807264A1 (en) * 2018-06-12 2021-04-21 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
IL288868B1 (en) * 2019-06-12 2024-10-01 Ryvu Therapeutics S A Next generation modulators of stimulator of interferon genes (STING)

Also Published As

Publication number Publication date
IL293527A (en) 2022-08-01
AU2020400010A1 (en) 2022-05-26
EP4073063A1 (en) 2022-10-19
CN114787147A (zh) 2022-07-22
CA3159968A1 (en) 2021-06-17
KR20220113473A (ko) 2022-08-12
AU2024200264A1 (en) 2024-02-01
AU2020400010B2 (en) 2024-01-25
JP7426486B2 (ja) 2024-02-01
US20230076506A1 (en) 2023-03-09
JP2023505878A (ja) 2023-02-13
WO2021116451A1 (en) 2021-06-17
MX2022007178A (es) 2022-07-13

Similar Documents

Publication Publication Date Title
BR112022010611A2 (pt) Compostos heterocíclicos como moduladores de estimulador de genes de interferon (sting)
BR112021024948A2 (pt) Moduladores de próxima geração de estimulador de genes de interferon (sting)
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112016016844A2 (pt) Compostos heterocíclicos
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
BR112018074815A2 (pt) piridinas substituídas com heteroarila e métodos de uso
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
MX2018004175A (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112015021027A2 (pt) compostos terapêuticos
BR112017019326A2 (pt) composto, composição, método para controlar um invertebrado praga e semente
BR112021025928A2 (pt) Métodos de preparação de ácido bempedoico e composições do mesmo
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
BR112017009595A2 (pt) morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
BR112017023080A2 (pt) compostos benzimidazolona e benzotiazolona e uso dos mesmos como moduladores do receptor de ampa